Boston Scientific wins patent infringement verdict.Boston Scientific The Boston Scientific Corporation (NYSE: BSX) (abbreviated BSC), is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a range of interventional medical specialties, including interventional cardiology, peripheral interventions, Corporation (Natick, MA) said that a United States District Court United States District Court In the U.S., any of the 94 trial courts of general jurisdiction in the federal judicial system. Each state, as well as the District of Columbia and the Commonwealth of Puerto Rico, has at least one federal district court. jury in Delaware found that Johnson & Johnson's (New Brunswick New Brunswick, province, Canada New Brunswick, province (2001 pop. 729,498), 28,345 sq mi (73,433 sq km), including 519 sq mi (1,345 sq km) of water surface, E Canada. , NJ) CYPHER See cipher. drug-eluting stent In cardiology, a drug-eluting stent is a stent (a scaffold) placed into narrowed, diseased coronary arteries that slowly releases a drug to block cell proliferation. This prevents scar-tissue–like growth that, together with clots (thrombus), could otherwise block the stented infringes a Boston Scientific patent and that Johnson & Johnson's CYPHER, Bx VELOCITY, Bx SONIC, and GENESIS stents infringe a second Boston Scientific patent. The jury also upheld the validity of both patents. The jury determined only liability; money damages and any other relief will be determined subsequently. The court has not yet set a post-verdict schedule. "We are very pleased with the jury's verdict. It confirms our belief that we have fundamental intellectual property covering drug-eluting stent technology and stent design," said Paul A. LaViolette, Boston Scientific's Chief Operating Officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. . Cordis Corporation (Miami, FL), a Johnson & Johnson company, will ask United States District Court Judge Sue Robinson to overturn the jury finding that Boston Scientific's Ding and Jang patents are valid and infringed by Cordis' stent products. If the verdict is not overturned, Cordis will appeal to the Court of Appeals for the Federal Circuit in Washington, DC. The Ding patent claims a two-layer drug coating on a drug eluting stent. The Jang patent claims specific stent geometry. A new jury will subsequently consider the amount of damages and whether the infringement was willful. Also, a jury will subsequently determine damages owed to Cordis, based on a jury finding last month that Boston Scientific's Taxus drug-eluting stent and its Liberte and Express bare metal 1. bare metal - New computer hardware, unadorned with such snares and delusions as an operating system, an HLL, or even assembler. Commonly used in the phrase "programming on the bare metal", which refers to the arduous work of bit bashing needed to create these basic tools stents infringe Cordis' Palmaz patent on balloon expandable stents. That jury also found the bare metal Liberte stent infringes another Cordis patent -- the Gray patent -- which relates to flexible balloon expandable stents and expires in 2016. Boston Scientific is a worldwide developer, manufacturer, and marketer of medical devices whose products are used in a broad range of interventional medical specialties. Cordis Corporation develops and manufactures interventional vascular technology. Through research, development and innovation, physicians worldwide are better able to treat the millions of patients who suffer from vascular disease. Boston Scientific Corporation +1-508-650-8569 www.bostonscientific.com Cordis Corporation +1-732-524-3350 www.cordis.com |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion